Neuronetics
American neuromodulation company
From Wikipedia, the free encyclopedia
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Russell 2000 Index component
 | |
| Company type | Public |
|---|---|
| Nasdaq: STIM Russell 2000 Index component | |
| Founded | 2003 |
| Headquarters | Malvern, PA, United States |
Key people | Keith J. Sullivan (President and CEO)[1][2] Stephen Furlong (CFO)[1]
Andrew Macan |
Number of employees | 167 As of March 31, 2018[update][4] |
| Website | neurostar |
Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."[5]
They manufacture a transcranial magnetic stimulation device, NeuroStar.[6] The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.[7][8]